Vc Thoughts, Health, Dna, Rna, Healthcare.
complicated diseases is possible. As more AAV-based therapies are approved, and more safety data becomes available, we expect more treatments to receive accelerated FDA approvals, similar to Sangamo Therapeutics’ α-Gal A program in Fabry’s Disease. Although there is no clear leader in the AAV-based